Skip to content
DataLookout
Menu

NCT05805371

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Nov 11, 2028 to Nov 11, 2029 Show 4 more changesShow less
    • Eligibility criteria expanded, about 21 words
    • Interventions: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (Biological), Biopsy (Procedure), Biospecimen Collection (Procedure)… to Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (Biological), Biopsy (Procedure), Biospecimen Collection (Procedure)…
    • Secondary endpoints: details revised at 2 of 9 entries
    • Study description revised
  2. Notable Start date: Jul 19, 2024 to Oct 9, 2024v13
  3. Notable Primary and study completion dates: Nov 11, 2026 to Nov 11, 2028v12
  4. Minor Start date changed from estimate of Nov 1, 2024 to Jul 19, 2024v11
  5. Notable Start date: Sep 1, 2024 to Nov 1, 2024
    • Primary and study completion dates moved earlier to Nov 11, 2026
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Notable Start date: Jun 12, 2024 to Sep 1, 2024v9
  2. Notable Start date: Apr 12, 2024 to Jun 12, 2024v8
  3. Notable Start date: Feb 12, 2024 to Apr 12, 2024v7
  4. Notable Primary completion date: Nov 9, 2025 to Aug 1, 2027
    • Start date: Dec 30, 2023 to Feb 12, 2024
    • Study completion date: Nov 9, 2025 to Jul 1, 2028
    v6
  5. Notable Start date: Oct 30, 2023 to Dec 30, 2023
    • Primary and study completion dates: Feb 26, 2026 to Nov 9, 2025
    v5
  6. Notable Start date: Jul 30, 2023 to Oct 30, 2023v4
  7. Notable Start date: May 30, 2023 to Jul 30, 2023v3
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 7, 2023 to May 30, 2023
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events
Timeframe: Post chimeric antigen receptor (CAR) T cell infusion up to 15 years
50% prostate specific antigen (PSA) level reduction
Timeframe: From baseline measurement up to 1 year post study treatment

Secondary (9)

Persistence of CAR T cells
Expansion of CAR T cells
PSCA tumor expression
Serum cytokine profile
Overall survival
Show 4 moreShow less
Progression-free survival
Disease response by PSA
Disease response by immune-modified Response Evaluation Criteria in Solid Tumors criteria
Disease response by Prostate Cancer Working Group criteria

Arms and interventions

Treatment plan I (PSCA CAR T-cells)Experimental

Patients undergo leukapheresis and lymphodepletion and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.

Treatment plan II (PSCA CAR T-cells, radiation)Experimental

Patients undergo leukapheresis, radiation in 2 doses, and lymphodepletion, and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.

Biologicals: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes

Procedures: Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lymphodepletion Therapy

Radiation: External Beam Radiation Therapy

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States